Patents by Inventor David Walter Barry
David Walter Barry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10094201Abstract: There is described a chemical injection system for a natural gas well. An instrument monitors the production of gas from the well and the flow of chemicals injected into the well. The instrument controls the on and off time of a chemical injection pump that is attached to a chemical injection tank. The control is based for certain chemicals such as a surfactant on the gas flow rate in the production piping. The user of the system inserts in the instrument the setpoints associated with the well's flow rate. These setpoints determine for a given flow rate the on time for the chemical injection pump. Other chemicals can also be injected into the well using the system and the injection for those chemicals may be based on other criteria such as temperature, water rate, oil rate or pipeline flow rate.Type: GrantFiled: April 6, 2015Date of Patent: October 9, 2018Assignee: ABB Schweiz AGInventor: David Walter Barry
-
Publication number: 20150285046Abstract: There is described a chemical injection system for a natural gas well. An instrument monitors the production of gas from the well and the flow of chemicals injected into the well. The instrument controls the on and off time of a chemical injection pump that is attached to a chemical injection tank. The control is based for certain chemicals such as a surfactant on the gas flow rate in the production piping. The user of the system inserts in the instrument the setpoints associated with the well's flow rate. These setpoints determine for a given flow rate the on time for the chemical injection pump. Other chemicals can also be injected into the well using the system and the injection for those chemicals may be based on other criteria such as temperature, water rate, oil rate or pipeline flow rate.Type: ApplicationFiled: April 6, 2015Publication date: October 8, 2015Applicant: ABB TECHNOLOGY AGInventor: David Walter Barry
-
Patent number: 6544961Abstract: The present invention relates to therapeutic combinations of 3S-[3R*(1R*,2S*)-[3 -[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (141W94), 3′-azido-3′-deoxythymidine (zidovudine) and (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.Type: GrantFiled: December 18, 1998Date of Patent: April 8, 2003Assignee: SmithKline Beecham CorporationInventors: Martha Heider St. Clair, David Walter Barry
-
Patent number: 6486136Abstract: The present invention relates to therapeutic combinations of [3R*(1R*,2S*)]-[3[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (141W94), 3′-azido-3′-deoxythymidine (zidovudine) and (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.Type: GrantFiled: December 18, 1998Date of Patent: November 26, 2002Assignee: SmithKline Beecham CorporationInventors: Martha Heider St. Clair, David Walter Barry
-
Patent number: 6417191Abstract: The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol (1592U89), 3′-azido-3′-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.Type: GrantFiled: September 30, 1997Date of Patent: July 9, 2002Assignee: GlaxoSmithKlineInventors: David Walter Barry, Martha Heider St. Clair
-
Patent number: 5885957Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: June 26, 1997Date of Patent: March 23, 1999Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5877163Abstract: A method of treating AIDS with 3'-azido-3'-deoxythymidine in combination with interleukin II or phosphonoformate is presented.Type: GrantFiled: July 10, 1997Date of Patent: March 2, 1999Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5683990Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir and AZT and 2-amino-9-(2-hydroxyethoxymethyl)purine or an ester thereof.Type: GrantFiled: August 21, 1986Date of Patent: November 4, 1997Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5643891Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: February 26, 1993Date of Patent: July 1, 1997Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman